Atreca, a preclinical biotech developing immunotherapies for solid tumors, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
The Redwood City, CA-based company was founded in 2010 and plans to list on the Nasdaq under the symbol BCEL. Atreca filed confidentially on April 24, 2019. Cowen, Evercore ISI and Stifel are the joint bookrunners on the deal. No pricing terms were disclosed.
